Who are Ademetionine IV+tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ademetionine 3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ademetionine-iv-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ademetionine IV+tablet — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ademetionine IV+tablet (Ademetionine IV+tablet) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Methyl donor / Hepatoprotective agent. Area: Hepatology / Gastroenterology.

phase 3 Methyl donor / Hepatoprotective agent S-adenosylmethionine synthetase substrate; indirect effects on methyltransferases and glutathione synthesis Hepatology / Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ademetionine IV+tablet (Ademetionine IV+tablet) — Abbott. Ademetionine is a methyl donor that replenishes cellular methylation capacity and supports hepatic function and neurotransmitter synthesis.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ademetionine IV+tablet TARGET	Ademetionine IV+tablet	Abbott	phase 3	Methyl donor / Hepatoprotective agent	S-adenosylmethionine synthetase substrate; indirect effects on methyltransferases and glutathione synthesis
Ademetionine 3	Ademetionine 3	Zhejiang Hisun Pharmaceutical Co. Ltd.	marketed	Methyl donor / Hepatoprotective agent	S-adenosylmethionine (SAM) / Methyltransferase cofactor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Methyl donor / Hepatoprotective agent class)

Abbott · 1 drug in this class
Zhejiang Hisun Pharmaceutical Co. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ademetionine IV+tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/ademetionine-iv-tablet. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab